Institute for Vaccine Safety - 2008 Immunization Schedule

Age ▶ ▼ Vaccine	7-10 years	11-12 years	13-18 years
Tetanus, Diphtheria, Pertussis	see footnote 1	Tdap	Tdap
Human Papillomavirus	see footnote 2	HPV (3 doses)	HPV Series
Meningococcal	MCV	MCV	MCV
Pneumococcal	PPSV
Influenza	Influenza (yearly)
Hepatitis A	Hep A Series
Hepatitis B	Hep B Series
Inactivated Poliovirus	IPV Series
Measles, Mumps, Rubella	MMR Series
Varicella	Varicella Series

This schedule indicates the recommended ages for routine administration of currently licensed vaccines, as of December 17, 2008, for children aged 7 through 18 years. Any dose not administered at the recommended age should be administered at a subsequent visit, when indicated and feasible. Licensed combination vaccines may be used whenever any component of the combination is indicated and other components are not contraindicated and if approved by the Food and Drug Administration for that dose of the series. Providers should consult the relevant Advisory Committee on Immunization Practices statement for detailed recommendations, including high-risk conditions: http://www.cdc.gov/vaccines/pubs/acip-list.htm. Clinically significant adverse events that follow immunization should be reported to the Vaccine Adverse Event Reporting System (VAERS). Guidance about how to obtain and complete a VAERS form is available at http://www.vaers.hhs.gov or by telephone, 800-822-7967.

2009 Schedules PDF (adobe acrobat)

2009 Schedule for ages 0-6 years | catch-up schedule
2009 Schedule for ages 7-18 years | catch-up schedule
2009 Schedule for Adults | special

1. Tetanus and diphtheria toxoids and acellular pertussis vaccine (Tdap). (Minimum age: 10 years for BOOSTRIX® and 11 years for ADACEL™)

Administer at age 11–12 years for those who have completed the recommended childhood DTP/DTaP vaccination series and have not received a tetanus and diphtheria toxoids vaccine (Td) booster dose.
Persons aged 13 through 18 years who have not received Tdap should receive a dose.

A 5-year interval from the last Td dose is encouraged when Tdap is used as a booster dose; however, a shorter interval may be used if pertussis immunity is needed.

2. Human papillomavirus vaccine (HPV). (Minimum age: 9 years)

Administer the first dose of the HPV vaccine series to females at age 11–12 years.
Administer the second dose 2 months after the first dose and the third dose 6 months after the first dose.
Administer the HPV vaccine series to females at age 13–18 years if not previously vaccinated.

3. Meningococcal vaccine.

Administer MCV4 at age 11–12 years and at age 13–18 years if not previously vaccinated.
Administer MCV4 to previously unvaccinated college freshmen living in dormitories.
MCV is recommended for children aged 2-10 years with terminal complement deficiencies or anatomic or functional asplenia and certain other high-risk groups. See MMWR 2005;54(No. RR-7).
Persons who received MPSV 5 or more years prior and remain at increased risk for meningococcal disease should be vaccinated with MCV.

4. Pneumococcal polysaccharide vaccine (PPV).

Administer to children with certain underlying medical conditions (see MMWR 1997;46[No. RR-8]), including a cochlear implant. A single revaccination should be administered to children with functional or anatomic asplenia or other immunocompromising condition after 5 years.

5. Influenza vaccine.

Administer annually to children aged 6 months through 18 years.
For healthy nonpregnant persons (i.e., those who do not have underlying medical conditions that predispose them to influenza complications) aged 2 through 49 years, either LAIV or TIV may be used.
Administer 2 doses (separated by at least 4 weeks) to children aged younger than 9 years who are receiving influenza vaccine for the first time or who were vaccinated for the first time during the previous influenza season but only received 1 dose.

6. Hepatitis A vaccine (HepA).

The 2 doses in the series should be administered at least 6 months apart.
HepA is recommended for children older than 1 year who live in areas where vaccination programs target older children or who are at increased risk of infection. See MMWR 2006;55(No. RR-7).

7. Hepatitis B vaccine (HepB).

Administer the 3-dose series to those who were not previously vaccinated.
A 2-dose series of Recombivax HB® is licensed for children aged 11–15 years.

8. Inactivated poliovirus vaccine (IPV).

For children who received an all-IPV or all-oral poliovirus (OPV) series, a fourth dose is not necessary if the third dose was administered at age ≥ 4 years.
If both OPV and IPV were administered as part of a series, a total of 4 doses should be administered, regardless of the child’s current age.

9. Measles, mumps, and rubella vaccine (MMR).

If not previously vaccinated, administer 2 doses of MMR during any visit, with ≥ 4 weeks between the doses.

10. Varicella vaccine.

Administer 2 doses of varicella vaccine to persons aged <13 years at least 3 months apart. Do not repeat the second dose, if administered >28 days after the first dose.
Administer 2 doses of varicella vaccine to persons aged >13 years at least 4 weeks apart.

Changes from 2007 Schedule

For meningococcal vaccines, the catch-up schedule for youths aged 13–18 years has been updated. MPSV4 is an acceptable alternative for short-term (i.e., 3–5 years) protection against meningococcal disease for persons aged 2–18 years.
The tetanus and diphtheria toxoids/tetanus and diphtheria toxoids and acellular pertussis vaccine (Td/Tdap) catch-up schedule for persons aged 7–18 years who received their first dose before age 12 months now indicates that these youths should receive 4 doses, with at least 4 weeks (not 8 weeks) between doses 2 and 3.
The catch-up bars for hepatitis B and Haemophilus influenzae type b conjugate vaccine have been deleted on the routine schedule for persons aged 0–6 years. The figure title refers users to the catch-up schedule (Table) for patients who fall behind or start late with vaccinations.

This page was last updated on January 12, 2010